Category: CovidienSyndicate content

Inside the Medtronic-Covidien deal: Contrasting styles brought the companies together

September 17, 2014 by Brian Johnson

A senior executive at Medtronic, vice president of corporate development Chris Cleary, explains how Covidien played "scrappy" upstart all the way to a $43 billion payout.

Inside the Medtronic-Covidien deal: Contrasting styles brought the companies together

Neurovascular: Covidien begins enrollment in 2 new trials

September 15, 2014 by Arezu Sarvestani

Covidien begins enrolling patients in clinical trials for its Pipeline embolization system as well as all its endovascular stroke devices.

Covidien begins enrollment for 2 new trials

Covidien (NYSE:COV) announced today that it enrolled the 1st patients in a pair of clinical trials evaluating the company's neurovascular technologies.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Treasury Secretary Lew nears decision on Medtronic's Covidien inversion deal

September 8, 2014 by Arezu Sarvestani

Washington D.C. is preparing to move on efforts to penalize companies that move their headquarters overseas to benefit from lower corporate tax rates.

Treasury Secretary Lew nears decision on Medtronic's Covidien inversion deal

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Covidien's new agreement takes patient monitoring into homes

September 4, 2014 by Arezu Sarvestani

Covidien penetrates home-based patient monitoring through an agreement licensing its ZephyrLIFE telehealth solutions to Geneia for integration into their @Home platform.

Covidien's new agreement takes patient monitoring into homes

Medtech titan Covidien (NYSE:COV) is breaching new ground in home care with its ZephyrLIFE remote monitoring platform, agreeing to license the technology to healthcare solutions company Geneia.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Failure of Medtronic's Symplicity-3 trial doesn't mean the end of renal denervation for hypertension | Medtech Wall Street news for the week of September 1, 2014

September 4, 2014 by MassDevice

Here's a look at some of the top Wall Street stories for medical device companies this week: Renal denervation isn't dead, despite Medtronic trial's failure; Baxter says HQ will stay in Illinois, stays coy on Boston plans; Private equity owners rebrand KCI, Systagenix, LifeCell as Acelity

Renal denervation isn't dead, despite Medtronic trial's failure

September 2, 2014 by Brad Perriello

Covidien acquires Sapheon and its VenaSeal device | The week in medtech M&A

September 3, 2014 by MassDevice

Here's a look at some of the top regulatory stories for medical device companies this week: Covidien acquires Sapheon and its VenaSeal varicose vein treatment; Medtronic to cover $58M tax tab for top execs in Covidien buy; Report: J&J puts Cordis on the block; Another Covidien shareholder sues over Medtronic deal; Allergan accedes to special meeting, asks court to block Valeant's vote

Covidien acquires Sapheon and its VenaSeal varicose vein treatment

August 28, 2014 by Brad Perriello

Medtech trends: The most talked about device makers in August 2014

September 3, 2014 by Arezu Sarvestani

MassDevice.com looks at the internet chatter surrounding the medical device industry with some of most searched-for companies of the last month.

chart

Click to enlarge.

MassDevice.com looked at some of the most talked-about medical device companies, based on trends in U.S. Google searches for the last 30 days.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp